Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases [PDF]
Turkish Journal of Hematology, 2010 OBJECTIVE: The cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is expressed on T lymphocytes, and inhibits the T-cell responses. In animal models, it has been shown that complete CTLA-4 deficiency was lethal due to massive infiltration of tissues by
Faruk Aktürk +2 more
doaj +4 more sources
CTLA-4 and targeted immunotherapy—a key link in the systemic influence of periodontitis: a mini review [PDF]
Frontiers in Dental MedicineCytotoxic T Lymphocyte Associated Protein 4 is a T cell-associated receptor that serves as an immune checkpoint molecule, downregulating immunosurveillance and propagating immune homeostasis.
Abirami Thanigaimalai +5 more
doaj +2 more sources
Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4) [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is the most important human immune checkpoint that modulates T cells activity and brings about immune-homeostasis.
Nazli Sotoudeh +4 more
doaj +1 more source
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. [PDF]
PLoS ONE, 2018 CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells.
Randi B Gombos +26 more
doaj +1 more source
Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach
Frontiers in Applied Mathematics and Statistics, 2022 Anti CTLA-4 therapy is aimed at blocking the Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a key cancer immunity cycle checkpoint. The mechanism of action of CTLA-4 may be described as a dynamic competition for the B7 ligand which, subsequently, interferes ...
Ivan Azarov +7 more
doaj +1 more source
Identification of CTLA-4-Positive Cells in the Human Tonsil
Cells, 2021 CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) was originally defined as a T-lymphocyte antigen and was used as a target in cancer immunotherapy. Unfortunately, the existence of CTLA-4 in cells other than T-lymphocytes is often overlooked. The goal
Markus Tiemann +3 more
doaj +1 more source
OncoImmunology, 2021 The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life
Aditya Arra +12 more
doaj +1 more source
mAbs, 2023 Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical inhibitory checkpoint molecule, and monoclonal antibodies (mAbs) targeting CTLA-4 that restore anti-tumor T cell immunity have achieved clinical success.
Jiawei Guan +16 more
doaj +1 more source
Molecules that inhibit T-cell functions: cytochemical localization and shuttling
European Journal of Histochemistry, 2009 Adaptive immune responses to antigens are mediated by specific receptors expressed on B cells (BCR’s) and T cells (TCR’s). Effector cells and memory cells are produced following a proliferative wave that accounts for clonal expansion.
G Santoro +7 more
doaj +3 more sources
CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression
Open Life Sciences, 2021 The recurrence rate of lymphoma is very high, and tumor stem cells may be an important mechanism. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can inhibit antitumor immunity and promote cancer progression, but its role and mechanism in lymphoma ...
Chen Yan +6 more
doaj +1 more source